Filing Details

Item 3 of the Schedule 13D is hereby amended and supplemented as follows: On January 24, 2025, the Issuer amended and restated the terms of each of the Amended Dragasac Warrants to purchase up to 652,981 Common Shares (as adjusted for the Reverse Stock Split (as defined in Amendment No. 3), such amended and restated warrants being the "Second Amended Dragasac Warrants") and the New Dragasac Warrants to purchase up to 535,274 Common Shares (as adjusted for the Reverse Stock Split, such amended and restated warrants being the "Amended New Dragasac Warrants") in order to adjust the exercise price of each from $2.4898 per Common Share to $2.07 per Common Share, which represents a 10% discount from the closing price of the Issuer's Common Shares on January 23, 2025. The foregoing summary of each of the Second Amended Dragasac Warrants and Amended New Dragasac Warrants does not purport to be complete and is qualified in its entirety by reference to the full text of each of the Second Amended Dragasac Warrants and Amended New Dragasac Warrants, each of which is attached hereto as an exhibit to this Amendment No. 5 and is incorporated by reference. On January 24, 2025, Dragasac elected to exercise, on a cash basis, the Second Amended Dragasac Warrants and Amended New Dragasac Warrants in full, and thereby acquired an aggregate 1,188,255 Common Shares from the Issuer for an aggregate purchase price of $2,459,687.85.

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The response to Item 3 of this Amendment No. 5 is incorporated by reference herein.

Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows: As of the date hereof, Dragasac may be deemed to beneficially own 6,335,630 Common Shares, or approximately 26.8% of the Common Shares outstanding. As of the date hereof, RWI may be deemed to beneficially own 3,600,000 Common Shares, or approximately 13.2% of the Common Shares outstanding, which consists entirely of Common Shares that RWI has the right to acquire upon exercise of warrants. As of the date hereof, Genting Berhad may be deemed to beneficially own 9,935,630 Common Shares, or approximately 36.4% of the Common Shares outstanding. This amount includes (i) 6,335,630 Common Shares held directly by Dragasac and (ii) 3,600,000 Common Shares that RWI has the right to acquire upon exercise of warrants. As of the date hereof, Mr. Lim may be deemed to beneficially own 9,938,161 Common Shares, or approximately 36.4% of the Common Shares outstanding. This amount includes (i) 6,335,630 Common Shares held directly by Dragasac, (ii) 3,600,000 Common Shares that RWI has the right to acquire upon exercise of warrants, and (iii) 2,531 Common Shares held directly by Mr. Lim. The percentages set forth herein are based on the sum of (i) 22,484,239 Common Shares outstanding as of December 2, 2024, based on information reported in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the Commission on December 6, 2024, (ii) 652,981 Common Shares issued to Dragasac upon exercise of the Second Amended Dragasac Warrants, and (iii) 535,274 Common Shares issued to Dragasac upon exercise of the Amended New Dragasac Warrants, plus, for RWI, Genting Berhad, and Mr. Lim, (iv) the 3,600,000 Common Shares issuable to RWI within sixty days upon exercise of warrants, with (iv) having been added to the Common Shares outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act.

Item 5(b) of the Schedule 13D is hereby amended and supplemented as follows: Dragasac, Genting Berhad, and Mr. Lim may be deemed to share the power to vote or direct the vote and the power to dispose or direct the disposition of, the 6,335,630 Common Shares held directly by Dragasac. RWI, Genting Berhad, and Mr. Lim may be deemed to share the power to vote or direct the vote and the power to dispose or direct the disposition of, the 3,600,000 Common Shares that RWI has the right to acquire upon exercise of warrants. Mr. Lim may be deemed to have the sole power to vote or direct the vote, and the sole power to dispose or direct the disposition of, the 2,531 Common Shares held directly by Mr. Lim.

Item 5(c) of the Schedule 13D is hereby amended and supplemented as follows: The response to Item 3 of this Amendment No. 5 is incorporated by reference herein. Other than as disclosed herein, the Reporting Persons have not effected any transactions in the Common Shares since the filing of Amendment No. 4.

Item 6 of the Schedule 13D is hereby amended and supplemented as follows: The response to Item 3 of this Amendment No. 5 is incorporated by reference herein. Except as otherwise set forth in the Schedule 13D, as amended by this Amendment No. 5, there are no contracts, arrangements, understandings, or relationships between the Reporting Persons named in Item 2 and any other person with respect to any securities of the Issuer, including but not limited to transfer or voting of any such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

Item 7 of the Schedule 13D is hereby amended and supplemented as follows: Exhibit 99.20 Second Amended Dragasac Warrants, dated January 24, 2025. Exhibit 99.21 Amended New Dragasac Warrants, dated January 24, 2025.